South Africa's Biovac to start making Pfizer-BioNTech vaccine in H2 2022 – CEO

Health News
FILE PHOTO: A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration

CAPE TOWN (Reuters) – South Africa’s Biovac Institute is aiming to start production of the mRNA COVID-19 vaccine developed by Pfizer and BioNTech in the second half of next year, its chief executive officer said on Wednesday.

Morena Makhoana told Reuters the Cape Town-based firm would ramp up production of the COVID-19 vaccine before reaching output of 100 million doses a year around early 2023.

Source: Read Full Article

Related posts:
  1. Japanese government committee approves Pfizer's COVID-19 vaccine – NHK
  2. Pfizer seeks U.S. approval to ease handling of COVID-19 vaccine
  3. FDA allows storage, transport of Pfizer vaccine at higher temperatures